Every compound, every number, one place.

Long-acting GLP-1 receptor agonist approved for type 2 diabetes and metabolic indications.

Dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and metabolic indications.

Triple agonist of GIP, GLP-1 and glucagon receptors in late-stage trials for obesity and metabolic disease.

Long-acting amylin analogue. Studied as monotherapy and combined with semaglutide (CagriSema).

Synthetic pentadecapeptide derived from a gastric protein. Studied for tendon, ligament and gut repair via angiogenesis and growth factor upregulation.

Synthetic fragment of Thymosin Beta-4. Studied for systemic tissue repair, cell migration and cardiac recovery models.

Naturally occurring copper-binding tripeptide. Studied for skin remodelling, collagen synthesis and wound repair.

Selective ghrelin receptor agonist that triggers pulsatile growth hormone release without significantly elevating cortisol or prolactin.

Tetra-substituted GHRH analogue with extended stability. Stimulates pituitary GH release, commonly paired with a GHRP.

Synthetic GHRH 1-29 fragment. Historically approved for paediatric GH deficiency diagnosis.

Potent synthetic hexapeptide GHRP with strong GH releasing activity.

Synthetic growth hormone releasing peptide with potent GH release and moderate appetite stimulation.

Synthetic hexapeptide GHRP with strong appetite stimulation. Older generation GHRP.

FDA approved GHRH analogue for reduction of excess abdominal fat in HIV associated lipodystrophy.

Modified C-terminal fragment of the endogenous growth hormone peptide. Studied for lipolytic activity without IGF-1 elevation.

Mitochondrial derived peptide encoded within the 12S rRNA. Studied for AMPK activation, insulin sensitivity and exercise capacity.

Anxiolytic peptide that reduces anxiety and promotes calm focus without sedation. Approved in Russia for anxiety disorders.

neurotrophic peptide that is studied for focus, memory and cognitive pathways. Approved in Russia for cognitive and neurological conditions.

Splice variant of IGF-1 released in response to mechanical stress on muscle tissue. Promotes satellite cell activation and muscle repair.

Potent anti-inflammatory peptide derived from alpha-MSH. Studied for gut health and inflammatory conditions.

Complex mixture of low molecular weight neuropeptides derived from porcine brain tissue. Provides neuroprotective and neurotrophic effects. Used clinically in some countries for neurological research.

BPC-157, an orally active synthetic peptide, is a stable gastric pentadecapeptide with significant protective effects on the gastrointestinal tract and various tissues, often studied for its healing properties.

Adamax is a synthetic neurotrophic peptide derived from Semax, with enhanced neuroprotective and cognitive-enhancing properties.

Mitochondria-targeted tetrapeptide that stabilises cardiolipin on the inner mitochondrial membrane. FDA approved as Forzinity (Sept 2025). Restores electron transport chain efficiency and improves cardiac and skeletal muscle function.

Telomerase-activating peptide researched for effects on cellular aging, circadian rhythm, and immune function.

Synthetic GnRH that stimulates pituitary release of LH and FSH, studied in gonadotropin and reproductive-axis research.

Naturally occurring 9-amino acid neuropeptide that enhances deep (delta wave) sleep and supports circadian rhythm regulation.

Dual glucagon and GLP-1 receptor agonist combining appetite suppression with increased energy expenditure. Shows promise for NASH/MASH.

Livagen is a synthetic tetrapeptide composed of lysine, glutamic acid, aspartic acid, and alanine (Lys-Glu-Asp-Ala), developed by Professor Vladimir Khavinson as a bioregulator peptide targeting the liver. The liver is central to metabolic homeostasis, oxidative-stress pathways, protein synthesis, and bile production, and hepatocyte function declines progressively with age. Livagen is proposed to normalise hepatocyte gene expression by interacting with DNA to modulate chromatin condensation and transcriptional activity in aging liver tissue. One notable proposed mechanism is the promotion of chromatin decondensation in heterochromatin regions of aging hepatocytes, potentially reactivating silenced genes involved in liver regeneration and metabolic function.

Complex mixture of low molecular weight neuropeptides derived from porcine brain tissue. Provides neuroprotective and neurotrophic effects. Used clinically in some countries for neurological research.

Naturally occurring peptide used clinically in over 30 countries for immune modulation. Approved for hepatitis B and C in some regions.

Mitochondrial-derived peptide with cytoprotective properties. Research suggests neuroprotective effects and potential role in age-related diseases.

Thymic peptide bioregulator used alongside Thymosin Alpha-1 for immune modulation. Part of the Khavinson peptide bioregulator research programme.

28-amino acid regulatory peptide involved in circadian rhythm, immune regulation, and neuroprotection. Studied for chronic inflammatory response syndrome (CIRS).

Vesugen is a synthetic tripeptide composed of lysine, glutamic acid, and aspartic acid (Lys-Glu-Asp), developed by Professor Vladimir Khavinson as a bioregulator peptide targeting the vascular system. It is designed to support endothelial function and microcirculation by modulating gene expression in vascular endothelial cells. Age-related vascular decline, characterised by endothelial dysfunction, reduced nitric oxide bioavailability, and impaired microcirculation, is a major contributor to cardiovascular disease and organ dysfunction. Vesugen is proposed to interact with DNA in endothelial cells to normalise transcription of genes involved in vascular homeostasis, including those regulating nitric oxide synthesis, angiogenesis, and endothelial integrity.

A synthetic BDNF mimetic tetrapeptide derived from Cerebrolysin that promotes neurogenesis without the observed effects in study models of full-length BDNF. Enhances dentate gyrus neurogenesis and improves spatial memory.

Synthetic 83-amino acid IGF-1 analog with extended half-life (20-30 hours) and enhanced potency. Stimulates hyperplasia.

Cortagen is a short synthetic bioregulator peptide developed by Professor Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology. It is designed to target the adrenal cortex, supporting the regulation of cortisol production and adrenal gland function. Bioregulator peptides are based on the concept that short peptide sequences derived from or mimicking endogenous tissue-specific peptides can restore gene expression patterns in aging or damaged tissues. Cortagen is proposed to normalise adrenal cortex function by interacting with DNA and modulating transcription of genes involved in androgen-pathway compoundsogenesis. While the bioregulator concept has theoretical appeal, the evidence base consists primarily of preclinical studies and observational reports from Russian clinical practice.

Neuropeptide studied for SNARE complex modulation in dermal and neuromuscular signalling research.

Peginesatide is a synthetic PEGylated peptide-based erythropoiesis-stimulating agent (ESA) that activates the erythropoietin (EPO) receptor to stimulate red blood cell production. Marketed briefly as Omontys, it was designed as an alternative to recombinant EPO products for treating anemia in chronic kidney disease. Unlike traditional ESAs, peginesatide is a synthetic dimeric peptide with no structural homology to erythropoietin, developed to avoid anti-EPO antibody-mediated pure red cell aplasia. It received FDA approval in March 2012 but was voluntarily withdrawn in February 2013 following reports of serious hypersensitivity reactions including fatal anaphylaxis. Research interest continues in modified formulations and the synthetic peptide EPO agonist concept remains scientifically valid.

Potent cognitive enhancer that promotes neurogenesis and synapse formation. Research shows high potency for BDNF-like effects.

Naturally occurring glycoprotein that binds and neutralises myostatin, a negative regulator of muscle-regulatory pathways. Research suggests muscle-regulatory pathway activity.

ACE-031 is a synthetic peptide that acts as a myostatin inhibitor. It promotes muscle-regulatory pathways and strength by blocking myostatin, a protein that limits muscle development.

Naturally occurring peptide that promotes angiogenesis, cell migration, and tissue repair. Well-studied for musculoskeletal healing.

Master antioxidant produced by every cell. SubQ form bypasses poor oral bioavailability. Studied in oxidative-stress, immune and dermal research.

Cell-penetrating peptide that disrupts the FOXO4-p53 interaction, selectively triggering apoptosis in senescent cells. Experimental senolytic agent.

An 11-amino acid peptide derived from erythropoietin (EPO) that activates the innate repair receptor (IRR) without stimulating erythropoiesis. Provides neuroprotection, anti-inflammatory, and tissue repair effects.

Pinealon is a synthetic tripeptide composed of glutamic acid, aspartic acid, and arginine (Glu-Asp-Arg, or EDR). Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, Pinealon is designed as a bioregulator peptide targeting the pineal gland. The pineal gland plays a central role in circadian rhythm regulation through endocrine signalling. Pinealon is proposed to normalise pineal gland function by modulating gene expression related to pineal hormone production, potentially supporting sleep quality, circadian rhythm integrity, and neuroprotection. As a short peptide, it is theorised to penetrate cells and interact with DNA to restore age-related decline in pineal function. Evidence remains limited to preclinical studies.

Master antioxidant produced by every cell. SubQ form bypasses poor oral bioavailability. Studied in oxidative-stress, immune and dermal research.

Oxyntomodulin-based dual glucagon-like peptide-1 (GLP-1) and glucagon (GCGR) receptor agonist, developed as IBI362 / LY3305677. Supplied strictly as laboratory reference material.

Melanocortin receptor agonist that modulates melanocortin-receptor signalling through central nervous system activation. FDA-approved (Vyleesi).

A synthetic BDNF mimetic tetrapeptide derived from Cerebrolysin that promotes neurogenesis without the observed effects in study models of full-length BDNF. Enhances dentate gyrus neurogenesis and improves spatial memory.

Anxiolytic peptide that reduces anxiety and promotes calm focus without sedation. Approved in Russia for anxiety disorders.

5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in cellular metabolism and energy regulation.

Vilon is a synthetic dipeptide consisting of lysine and glutamic acid (Lys-Glu), developed by Professor Vladimir Khavinson as a bioregulator peptide targeting the thymus gland. The thymus is the primary organ responsible for T-cell maturation and plays a critical role in adaptive immune function. With aging, the thymus undergoes involution, leading to progressive immunosenescence characterised by declining T-cell diversity and impaired immune surveillance. Vilon is proposed to modulate thymic gene expression, potentially restoring aspects of thymic function and supporting T-cell differentiation. As a dipeptide bioregulator, it represents the smallest functional unit in the Khavinson bioregulation framework, theorised to interact with DNA to normalise immune gene expression.

Natural peptide hormone that promotes bonding, reduces stress/anxiety, and enhances emotional connection and social behaviour.

Synthetic copper tripeptide analog of GHK-Cu. Stimulates collagen production, improves skin elasticity, and supports wound healing with enhanced stability over its parent compound.

TREK-1 channel blocker with rapid antidepressant and pro-cognitive effects. Research suggests faster onset than traditional antidepressants.

GHRH analogue. Stimulates steady GH release.

A synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that activates MC1R for photoprotection. EMA-approved (Scenesse) for erythropoietic protoporphyria (EPP). The most regulatory-advanced melanocortin peptide.

GHRH analogue. Stimulates steady GH release.